Roche has entered into an agreement with a privately held biopharmaceutical company, Chiasma, to develop and commercialize Chiasma’s proprietary oral product Octreolin, initially for acromegaly and ...

A NUMBER of theories have emerged from time to time attempting to visualize the exact mechanism involved during crossing-over, which is now known to be the sole agent conditioning the formation of the ...

An increase of chiasma frequency or recombination has been found as a rule after treatment with deoxyadenosine at zygotene, again except with Chlamydomonas, when there was a decline in recombination.